Adaptimmune Therapeutics 的 afami-cel 疗法治疗晚期滑膜肉瘤获得 FDA 优先审查，如果获得批准，这可能成为美国实体瘤治疗的第一个工程化 T 细胞疗法。 Adaptimmune Therapeutics receives FDA priority review for afami-cel therapy in treating advanced synovial sarcoma, which could be the first engineered T-cell therapy for US solid tumor treatment if approved.

Adaptimmune Therapeutics 的生物制品许可申请已获得 FDA 优先审查批准，用于治疗晚期滑膜肉瘤（一种罕见的癌症）。 Adaptimmune Therapeutics has received approval for priority review from the FDA for its biologics license application to treat advanced synovial sarcoma, a rare type of cancer. 该公司的 afami-cel 疗法的处方药使用者付费法案目标行动日期定为 8 月 4 日。 The company's afami-cel therapy has a Prescription Drug User Fee Act target action date set for August 4. 如果获得批准，afami-cel 将成为美国市场上第一个用于治疗实体瘤的工程化 T 细胞疗法。 If approved, afami-cel would be the first engineered T-cell therapy on the US market for the treatment of solid tumors.